Analysts say loss of Toprol XL patent a significant threat to AstraZeneca

Share this article:
AstraZeneca faces a significant risk of losing US patent protection on its top selling heart drug Toprol XL (metoprolol succinate), according to analysts from Deutsche Bank. The analysts estimate there is around a 40 percent chance AstraZeneca will lose a ruling on the drug, according to a report from Reuters today. AstraZeneca has maintained its expectation of exclusivity on Toprol XL to hold until Sept. 2007, when US patents expire. The challenges to Toprol XL patents come from KV Pharmaceutical, Andrx Corp. and Eon Labs, a unit of Novartis. Sales of Toprol XL are expected to total around $1.3 billion in 2005. Generic drug makers have also recently challenged AstraZeneca’s two biggest sellers, the anitulcerant Nexium (esomeprazole magnesium delayed-release capsules), and Seroquel (quetiapine fumarate) for schizophrenia. In November AstraZeneca filed a lawsuit against Ranbaxy Laboratories in an attempt to stop the Indian drug maker from launching a copycat version of its top-selling medicine Nexium. Also in November, AstraZeneca filed a lawsuit against Teva Pharmaceuticals for infringement of AstraZeneca's substance patent protecting Seroquel.
Share this article:

Email Newsletters

More in News

Star Group merges with Vox Medica, Calcium NYC

Star Group merges with Vox Medica, Calcium NYC

The newly formed group will be known as Calcium with Steve Michaelson, formerly of Rosetta Wishbone, at the helm.

Survey finds pay doesn't make doctors happy

Survey finds pay doesn't make doctors happy

Medscape's survey of over 24,000 physicians found that a paycheck is not necessarily linked to a physician's professional satisfaction.

CDC sees declines in some diabetes complications

CDC sees declines in some diabetes complications

Centers for Disease Control data shows that diabetes complications including heart attack and amputation fell in the twenty years between 1990 and 2010. The bad news: the number of diagnosed ...